$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000158364821000047 Filed on November 02, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$8.443M	$4.057M	$1.880M
YoY Change	349.1%	38.04%	-89.11%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.085M	$4.132M	$3.670M
YoY Change	11.31%	0.29%	-18.08%
% of Gross Profit
Research & Development	$15.36M	$18.94M	$10.62M
YoY Change	44.6%	60.18%	-24.79%
% of Gross Profit
Depreciation & Amortization	$609.0K	$608.0K	$690.0K
YoY Change	-11.74%	-18.93%	165.38%
% of Gross Profit
Operating Expenses	$19.44M	$23.07M	$14.29M
YoY Change	36.05%	44.74%	-23.17%
Operating Profit		-$19.01M
YoY Change		46.26%
Interest Expense	-$6.000K	$4.000K	$10.00K
YoY Change	-160.0%	-92.73%	-97.37%
% of Operating Profit
Other Income/Expense, Net	$378.0K	$678.0K	-$1.830M
YoY Change	-120.66%	-150.63%	-1116.67%
Pretax Income	-$9.532M	-$16.54M	-$14.24M
YoY Change	-33.06%	15.8%	1749.35%
Income Tax			$160.0K
% Of Pretax Income
Net Earnings	-$9.532M	-$16.50M	-$14.40M
YoY Change	-33.81%	15.38%	1770.13%
Net Earnings / Revenue	-112.9%	-406.7%	-765.96%
Basic Earnings Per Share		-$0.24
Diluted Earnings Per Share	-$132.1K	-$0.24	-$257.1K
COMMON SHARES
Basic Shares Outstanding	72.06M shares	67.73M shares	55.97M shares
Diluted Shares Outstanding		67.73M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$117.8M	$125.1M	$70.40M
YoY Change	67.28%	51.39%	-32.44%
Cash & Equivalents	$117.8M	$125.1M	$70.44M
Short-Term Investments			$0.00
Other Short-Term Assets	$6.548M	$5.949M	$3.600M
YoY Change	81.89%	91.9%	-12.2%
Inventory
Prepaid Expenses
Receivables	$3.313M	$6.646M	$1.706M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$127.6M	$137.6M	$75.72M
YoY Change	68.55%	55.26%	-34.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.12M	$19.61M	$22.05M
YoY Change	-13.26%	-8.33%	13.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.904M	$2.950M	$3.309M
YoY Change	-12.24%	48.02%	5.18%
Total Long-Term Assets	$25.94M	$26.54M	$29.29M
YoY Change	-11.45%	-1.95%	12.29%
TOTAL ASSETS
Total Short-Term Assets	$127.6M	$137.6M	$75.72M
Total Long-Term Assets	$25.94M	$26.54M	$29.29M
Total Assets	$153.6M	$164.2M	$105.0M
YoY Change	46.23%	41.88%	-25.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.609M	$3.562M	$1.787M
YoY Change	381.76%	65.37%	-69.21%
Accrued Expenses	$14.83M	$19.69M	$7.731M
YoY Change	91.86%	162.89%	-22.25%
Deferred Revenue	$25.12M	$26.45M	$12.63M
YoY Change	98.91%	163.31%	12.18%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$50.56M	$49.70M	$22.15M
YoY Change	128.32%	152.43%	-17.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$6.000K
YoY Change	-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$6.000K
YoY Change	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$50.56M	$49.70M	$22.15M
Total Long-Term Liabilities	$0.00	$0.00	$6.000K
Total Liabilities	$102.8M	$110.3M	$73.98M
YoY Change	38.96%	53.17%	-17.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$257.1M	-$247.6M	-$211.4M
YoY Change	21.64%	25.68%	21.37%
Common Stock	$307.1M	$302.7M	$242.7M
YoY Change	26.51%	25.34%	6.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$50.76M	$53.85M	$31.03M
YoY Change
Total Liabilities & Shareholders Equity	$153.6M	$164.2M	$105.0M
YoY Change	46.23%	41.88%	-25.58%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$9.532M	-$16.50M	-$14.40M
YoY Change	-33.81%	15.38%	1770.13%
Depreciation, Depletion And Amortization	$609.0K	$608.0K	$690.0K
YoY Change	-11.74%	-18.93%	165.38%
Cash From Operating Activities	-$10.94M	-$14.48M	-$13.42M
YoY Change	-18.45%	91.33%	-4.01%
INVESTING ACTIVITIES
Capital Expenditures	-$342.0K	-$350.0K	-$580.0K
YoY Change	-41.03%	-141.67%	-50.43%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$15.43M
YoY Change	-100.0%	-100.0%	-2273.24%
Cash From Investing Activities	-$342.0K	-$350.0K	$14.85M
YoY Change	-102.3%	-101.91%	-889.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.901M	21.92M	80.00K
YoY Change	6026.25%	127.82%	-99.75%
NET CHANGE
Cash From Operating Activities	-10.94M	-14.48M	-13.42M
Cash From Investing Activities	-342.0K	-350.0K	14.85M
Cash From Financing Activities	4.901M	21.92M	80.00K
Net Change In Cash	-6.385M	7.082M	1.510M
YoY Change	-522.85%	-65.28%	-90.45%
FREE CASH FLOW
Cash From Operating Activities	-$10.94M	-$14.48M	-$13.42M
Capital Expenditures	-$342.0K	-$350.0K	-$580.0K
Free Cash Flow	-$10.60M	-$14.13M	-$12.84M
YoY Change	-17.43%	68.06%	0.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001583648
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37471
	dei	Entity Registrant Name EntityRegistrantName	PIERIS PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0784346
	dei	Entity Address Address Line1 EntityAddressAddressLine1	255 State Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	9th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Country EntityAddressCountry	US
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02109
	dei	City Area Code CityAreaCode	857
	dei	Local Phone Number LocalPhoneNumber	246-8998
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	PIRS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	72062173	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125052000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70436000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6646000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1706000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5949000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3579000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	137647000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	75721000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19613000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22046000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3974000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3934000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2950000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3309000	USD
CY2021Q3	us-gaap	Assets Assets	164184000	USD
CY2020Q4	us-gaap	Assets Assets	105010000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3562000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1787000	USD
CY2021Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	19685000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7731000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	26449000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12627000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	49696000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22145000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	46190000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	35900000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14445000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15932000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	110331000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	73983000	USD
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	72000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	56000	USD
CY2021Q3	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	1814000	USD
CY2020Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	0	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	302591000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	242672000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	616000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-295000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-247612000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-211406000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	53853000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	31027000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	164184000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	105010000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2783000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2578000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	20189000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	22393000	USD
CY2021Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1274000	USD
CY2020Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	361000	USD
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	2786000	USD
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	5053000	USD
CY2021Q3	us-gaap	Revenues Revenues	4057000	USD
CY2020Q3	us-gaap	Revenues Revenues	2939000	USD
	us-gaap	Revenues Revenues	22975000	USD
	us-gaap	Revenues Revenues	27446000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18937000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11822000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51299000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35913000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4132000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4116000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12508000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13043000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	23069000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	15938000	USD
	us-gaap	Operating Expenses OperatingExpenses	63807000	USD
	us-gaap	Operating Expenses OperatingExpenses	48956000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19012000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12999000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40832000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	10000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	503000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21510000	USD
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	4000	USD
CY2020Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	55000	USD
CY2021Q3	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	1794000	USD
CY2020Q3	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	0	USD
	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	2590000	USD
	pirs	Revenue Not From Contract With Customer Grant Income RevenueNotFromContractWithCustomerGrantIncome	0	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	678000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1339000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2026000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1823000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-16536000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-14283000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-36206000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22830000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	382000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	632000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	911000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1462000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-350000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-249000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16154000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14001000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35295000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21617000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67730000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67730000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54340000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54340000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62019000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62019000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53976000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53976000	shares
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	46672000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-14283000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	632000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-350000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1396000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	43691000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	46721000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-16536000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	382000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1370000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	566000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	53853000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	51352000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22830000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1462000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-249000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3916000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	271000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	145000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	43691000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	31027000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-36206000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	911000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3895000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	858000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	96000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	837000	USD
	pirs	Stock Issued During Period Value Conversion Of Preferred Stock StockIssuedDuringPeriodValueConversionOfPreferredStock	0	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	53853000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-36206000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22830000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1850000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1623000	USD
	pirs	Operating Lease Right Of Use Asset Accretion OperatingLeaseRightOfUseAssetAccretion	70000	USD
	pirs	Operating Lease Right Of Use Asset Accretion OperatingLeaseRightOfUseAssetAccretion	103000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3895000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3916000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-26000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	293000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	607000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-33789000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	14792000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3284000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32479000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2148000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	67687000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	41178000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-607000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24361000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	858000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	271000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	837000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	96000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	145000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	18913000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1200000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1800000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	33522000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9624000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54226000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10040000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2287000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2708000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	54616000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4630000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70436000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62260000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125052000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66890000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2021Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	125100000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-319000	USD
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	0	USD
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	370000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-16500000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-14300000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-247600000	USD
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27861000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	The Company has no financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.
CY2021Q3	us-gaap	Revenues Revenues	4057000	USD
CY2020Q3	us-gaap	Revenues Revenues	2939000	USD
	us-gaap	Revenues Revenues	22975000	USD
	us-gaap	Revenues Revenues	27446000	USD
CY2017Q2	pirs	Number Of Technology Licenses NumberOfTechnologyLicenses	5	leaseAgreement
CY2017Q1	pirs	Number Of Separate Performance Obligations NumberOfSeparatePerformanceObligations	1	performanceObligation
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	100000	USD
CY2021Q3	pirs	Additions To Contract With Customer Liability AdditionsToContractWithCustomerLiability	1500000	USD
	pirs	Additions To Contract With Customer Liability AdditionsToContractWithCustomerLiability	31600000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1900000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3500000	USD
CY2021Q3	us-gaap	Grants Receivable GrantsReceivable	14200000	EUR
CY2021Q3	us-gaap	Grants Receivable GrantsReceivable	17000000	USD
CY2021Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	34900000	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	64000000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-200000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26903000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7290000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5815000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19613000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22046000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2732000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1220000	USD
CY2021Q3	pirs	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	2543000	USD
CY2020Q4	pirs	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	0	USD
CY2021Q3	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	8422000	USD
CY2020Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	2001000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2914000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2759000	USD
CY2021Q3	pirs	Accrued License Obligations Current AccruedLicenseObligationsCurrent	1655000	USD
CY2020Q4	pirs	Accrued License Obligations Current AccruedLicenseObligationsCurrent	358000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1032000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1030000	USD
CY2021Q3	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	165000	USD
CY2020Q4	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	128000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	222000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	235000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19685000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7731000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36700000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	37300000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56002815	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71504630	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71504630	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56002815	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15617	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15617	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	14429	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	14429	shares
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	370000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	360000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	1126000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	1134000	USD
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	198000	USD
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	192000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	562000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	536000	USD
CY2021Q3	us-gaap	Lease Cost LeaseCost	568000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	552000	USD
	us-gaap	Lease Cost LeaseCost	1688000	USD
	us-gaap	Lease Cost LeaseCost	1670000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y8M12D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	1900000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	1500000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	624000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2527000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2288000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2288000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2288000	USD
CY2021Q3	pirs	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	15065000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	25080000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9604000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	15476000	USD

Files In Submission

Name	View Source	Status
0001583648-21-000047-index-headers.html	Edgar Link	pending
0001583648-21-000047-index.html	Edgar Link	pending
0001583648-21-000047.txt	Edgar Link	pending
0001583648-21-000047-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pirs-20210930.htm	Edgar Link	pending
pirs-20210930.xsd	Edgar Link	pending
pirs-20210930_cal.xml	Edgar Link	unprocessable
pirs-20210930_def.xml	Edgar Link	unprocessable
pirs-20210930_htm.xml	Edgar Link	completed
pirs-20210930_lab.xml	Edgar Link	unprocessable
pirs-20210930_pre.xml	Edgar Link	unprocessable
pirs9-30x21ex311.htm	Edgar Link	pending
pirs9-30x21ex312.htm	Edgar Link	pending
pirs9-30x21ex321.htm	Edgar Link	pending
pirs9-30x21ex322.htm	Edgar Link	pending
pirs_9-30x21ex101.htm	Edgar Link	pending
pirs_9-30x21ex101001.jpg	Edgar Link	pending
pirs_9-30x21ex101002.jpg	Edgar Link	pending
pirs_9-30x21ex101003.jpg	Edgar Link	pending
pirs_9-30x21ex101004.jpg	Edgar Link	pending
pirs_9-30x21ex101005.jpg	Edgar Link	pending
pirs_9-30x21ex101006.jpg	Edgar Link	pending
pirs_9-30x21ex101007.jpg	Edgar Link	pending
pirs_9-30x21ex101008.jpg	Edgar Link	pending
pirs_9-30x21ex101009.jpg	Edgar Link	pending
pirs_9-30x21ex101010.jpg	Edgar Link	pending
pirs_9-30x21ex101011.jpg	Edgar Link	pending
pirs_9-30x21ex101012.jpg	Edgar Link	pending
pirs_9-30x21ex101013.jpg	Edgar Link	pending
pirs_9-30x21ex101014.jpg	Edgar Link	pending
pirs_9-30x21ex101015.jpg	Edgar Link	pending
pirs_9-30x21ex101016.jpg	Edgar Link	pending
pirs_9-30x21ex101017.jpg	Edgar Link	pending
pirs_9-30x21ex102.htm	Edgar Link	pending
pirs_9-30x21ex102001.jpg	Edgar Link	pending
pirs_9-30x21ex102002.jpg	Edgar Link	pending
pirs_9-30x21ex102003.jpg	Edgar Link	pending
pirs_9-30x21ex102004.jpg	Edgar Link	pending
pirs_9-30x21ex102005.jpg	Edgar Link	pending
pirs_9-30x21ex102006.jpg	Edgar Link	pending
pirs_9-30x21ex102007.jpg	Edgar Link	pending
pirs_9-30x21ex102008.jpg	Edgar Link	pending
pirs_9-30x21ex102009.jpg	Edgar Link	pending
pirs_9-30x21ex102010.jpg	Edgar Link	pending
pirs_9-30x21ex102011.jpg	Edgar Link	pending
pirs_9-30x21ex102012.jpg	Edgar Link	pending
pirs_9-30x21ex102013.jpg	Edgar Link	pending
pirs_9-30x21ex102014.jpg	Edgar Link	pending
pirs_9-30x21ex102015.jpg	Edgar Link	pending
pirs_9-30x21ex102016.jpg	Edgar Link	pending
pirs_9-30x21ex102017.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

2021 Q4 Form 10-Q Financial Statement

#000158364821000047 Filed on November 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS PIERIS PHARMACEUTICALS, INC. Stock $pirs

2021 Q4 Form 10-Q Financial Statement

#000158364821000047 Filed on November 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs